Metsera (MTSR) Competitors $14.00 +0.92 (+7.03%) As of 04/11/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock MTSR vs. LEGN, TGTX, TLX, BPMC, SRPT, AXSM, KRYS, NUVL, VRNA, and GRFSShould you be buying Metsera stock or one of its competitors? The main competitors of Metsera include Legend Biotech (LEGN), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Axsome Therapeutics (AXSM), Krystal Biotech (KRYS), Nuvalent (NUVL), Verona Pharma (VRNA), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Metsera vs. Legend Biotech TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Sarepta Therapeutics Axsome Therapeutics Krystal Biotech Nuvalent Verona Pharma Grifols Metsera (NASDAQ:MTSR) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability. Does the MarketBeat Community prefer MTSR or LEGN? Legend Biotech received 84 more outperform votes than Metsera when rated by MarketBeat users. However, 100.00% of users gave Metsera an outperform vote while only 72.13% of users gave Legend Biotech an outperform vote. CompanyUnderperformOutperformMetseraOutperform Votes4100.00% Underperform VotesNo VotesLegend BiotechOutperform Votes8872.13% Underperform Votes3427.87% Is MTSR or LEGN more profitable? Metsera has a net margin of 0.00% compared to Legend Biotech's net margin of -66.92%. Metsera's return on equity of 0.00% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets MetseraN/A N/A N/A Legend Biotech -66.92%-29.69%-19.45% Does the media refer more to MTSR or LEGN? In the previous week, Legend Biotech had 16 more articles in the media than Metsera. MarketBeat recorded 20 mentions for Legend Biotech and 4 mentions for Metsera. Legend Biotech's average media sentiment score of 1.36 beat Metsera's score of 0.22 indicating that Legend Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metsera 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Legend Biotech 14 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of MTSR or LEGN? 70.9% of Legend Biotech shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts recommend MTSR or LEGN? Metsera currently has a consensus price target of $47.00, suggesting a potential upside of 235.71%. Legend Biotech has a consensus price target of $79.00, suggesting a potential upside of 146.88%. Given Metsera's stronger consensus rating and higher possible upside, equities research analysts plainly believe Metsera is more favorable than Legend Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metsera 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Legend Biotech 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92 Which has higher earnings and valuation, MTSR or LEGN? Metsera has higher earnings, but lower revenue than Legend Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetseraN/AN/AN/AN/AN/ALegend Biotech$627.24M9.37-$518.25M-$0.48-66.67 SummaryLegend Biotech beats Metsera on 7 of the 13 factors compared between the two stocks. Remove Ads Get Metsera News Delivered to You Automatically Sign up to receive the latest news and ratings for MTSR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTSR vs. The Competition Export to ExcelMetricMetseraPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.47B$6.23B$5.25B$7.52BDividend YieldN/A3.04%5.34%4.30%P/E RatioN/A6.6321.3617.69Price / SalesN/A218.18366.3293.44Price / CashN/A65.6738.1534.64Price / BookN/A5.716.283.89Net IncomeN/A$141.10M$3.19B$247.17M7 Day Performance-16.67%0.11%0.66%1.77%1 Month Performance-45.69%-16.19%-11.10%-8.64%1 Year PerformanceN/A-18.28%4.51%-4.07% Metsera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTSRMetseraN/A$14.00+7.0%$47.00+235.7%N/A$1.47BN/A0.0081LEGNLegend Biotech2.6298 of 5 stars$32.00+2.3%$79.00+146.9%-41.8%$5.88B$627.24M-33.681,070Analyst ForecastNews CoveragePositive NewsGap DownTGTXTG Therapeutics3.2586 of 5 stars$36.71+2.0%$40.67+10.8%+148.7%$5.77B$329.00M-367.06290Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.65+1.5%$22.00+32.1%N/A$5.62B$783.21M0.00N/ABPMCBlueprint Medicines2.5442 of 5 stars$80.84+0.7%$124.95+54.6%-12.4%$5.17B$508.82M-74.85640Analyst ForecastPositive NewsGap DownHigh Trading VolumeSRPTSarepta Therapeutics4.7803 of 5 stars$51.03+1.4%$161.83+217.1%-59.0%$4.95B$1.90B40.82840Quiet Period ExpirationNews CoverageHigh Trading VolumeAXSMAxsome Therapeutics4.4979 of 5 stars$98.06+2.5%$169.80+73.2%+36.7%$4.78B$385.69M-16.37380Analyst RevisionKRYSKrystal Biotech4.7907 of 5 stars$165.00+2.7%$220.00+33.3%-8.3%$4.75B$290.52M55.18210NUVLNuvalent2.1247 of 5 stars$66.29+6.9%$113.44+71.1%-2.5%$4.75BN/A-19.1040Positive NewsVRNAVerona Pharma1.6087 of 5 stars$57.71+7.0%$69.14+19.8%+256.9%$4.66B$42.28M-30.0630GRFSGrifols3.5285 of 5 stars$6.76+3.7%N/A+1.7%$4.65B$7.21B5.7826,300Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies LEGN Alternatives TGTX Alternatives TLX Alternatives BPMC Alternatives SRPT Alternatives AXSM Alternatives KRYS Alternatives NUVL Alternatives VRNA Alternatives GRFS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTSR) was last updated on 4/12/2025 by MarketBeat.com Staff From Our PartnersDeFi Coin on Verge of Breakout!Crypto’s down — but the fundamentals aren’t. Strategic investors are using this dip to scoop up undervalued...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredWARNING to All American InvestorsForget the headlines about the "trade war." This is where a real military showdown between China and the U....Behind the Markets | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredPlease — Don’t PanicMarkets are in turmoil — but TradeSmith CEO Keith Kaplan says panic isn’t the answer. Instead, he believes thi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metsera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metsera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MTSR Stock Free MTSR Stock Alerts